Advertisement

Topics

Companies Related to "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" [Most Relevant Company Matches] - Page: 20 RSS

17:00 EDT 23rd March 2019 | BioPortfolio

Here are the most relevant search results for "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma" found in our extensive corporate database of over 50,000 company records.

Showing "Safety Immune Tumor Response Multi component Immune Based" Companies 476–500 of 8,100+

Probably Relevant

Prepared Response, Inc.

Prepared Response Inc. develops emergency preparedness solutions that enable police, fire, and other emergency responders to save lives and mitigate property damage. The company's flagship product, Rapid Responder(R), runs on laptop computers and allows first responders to instantly access secure, critical facility information including tactical, site and floor plans, aerial and 360 degree imagery...


NovImmune SA

NovImmune SA (‘NovImmune’) is a drug discovery and development company with a focus on therapeutic mAbs for inflammatory diseases and immune-related disorders. NovImmune has generated, to date, seven proprietary mAbs. The pipeline is a balance of preclinical and clinical compounds, with a mix of both clinically validated as well as novel targets....

Sigilon Therapeutics

Sigilon Therapeutics is creating a new class of living therapeutics to transform the lives of patients with a wide range of chronic diseases, including hemophilia, Type 1 diabetes and lysosomal storage disorders. Our proprietary platform is designed to restore healthy cell and organ function through the implantation of immune-shielded and specially enginee...


Lifeblood Medical,Inc

We carry an extensive line of high quality serum and reagents to the research community at competitive prices. Our products include Serum (including United States and Australian Fetal Bovine Serum), Serum Enhancers (DMEM and RPMI), Antibiotics, Specialty Media and Customized Applications. Our full line of proprietary products will consist of LIFOR® and its derivatives, which will be targeted towa...

Cardax Pharmaceuticals

Cardax is a development stage life sciences company that devotes substantially all of its efforts to developing nutraceutical and pharmaceutical products that provide the anti-inflammatory benefits of steroids or NSAIDS, but with exceptional safety profiles, as conferred by U.S. Food and Drug Administration (“FDA”) Generally Recognized as Safe (...

Corixa Corporation

Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune disease, cancer and infectious disease by understanding and directing the immune system. Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis...

Biota Holdings Limited

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza. Biota research breakthroughs have included novel nucleoside analogues designe...

AlphaGenix, Inc

AlphaGenix is a provider of immunological products for the life science industry. These products cover virtually every area of biology including apoptosis, cancer, cardiology, cell cycle/regulation, DNA repair, immune system, infectious diseases, neuroscience, signal transduction and transcription factors. In addition, the company provides custom immunology services that include hybridoma develop...

Synedgen Inc.

Synedgen Inc. is developing a new class of drugs with the ability to suppress inflammation, reduce infection and improve healing in the gastrointestinal tract and pulmonary tree and to reduce damage and inflammation due to chemical, radiological or physical damage using the science of glycomics - the study of complex sugar structure and function. Synedgen ...

Hughes Telematics, Inc.

Hughes Telematics, Inc. (“HTI”) (OTCBB: HUTC and HUTCW) is a leader in implementing the next generation of connected services. Centered on a core platform of safety and security, the company offers a portfolio of location-based services for consumers, manufacturers, fleets and dealers through two-way wireless connectivity. Networkfleet, Inc., a wholly ...

Agilvax

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critic...

Agilvax, Inc.

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critic...

Oxford BioMedica plc

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and wi...

University of Utah Health Care

University HealthSystem Consortium, based in Oak Brook, Ill., a suburb of Chicago, includes 107 AMCs (academic medical centers) and 241 of their affiliated hospitals in its membership, representing more than 90 percent of the nation’s nonprofit AMCs. The Consortium provides data products and services to support clinical, operational, financial, and su...

Molecular Response LLC

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and cost of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated into existing ...

Biomed Pharmaceuticals

The Company is a leading pharmacy provider of intravenous and injectable medications for patients with chronic disorders. Biomed treats a variety of immune deficient and autoimmune disorders through Intravenous Immunoglobulin (“IVIG”) therapy, as well as hemophilia and Rheumatoid Arthritis. In addition to filling a patient’s prescriptions, Biomedâ...

UL’s Integrated Health and Safety Institute

Founded in June 2015, UL’s Integrated Health and Safety Institute (IHSI) is the first private sector not-for-profit institute dedicated to advancing the integration of workplace health and safety programs. IHSI provides world-class research, guidance, standards, and education to assist employers in integrating their health, safety and worker well-bein...

Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company focused on the development, manufacture and commercialization of vaccines and antibody therapies that assist the body’s immune system to prevent or treat disease. Emergent’s marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Ad...

Nurse Response

Nurse Response provides invaluable telehealth services for physicians, hospitals, managed care providers, academic institutions and employee health. Programs increase accessibility of healthcare while decreasing overall costs through nurse assessment, health information, teaching and referral. www.nurseresponse.com

Forum for Collaborative HIV Research

Now part of the University of California (UC), Berkeley School of Public Health and based in Washington, DC, the Forum was founded in 1997 as the outgrowth of the Keystone Center's report "The Keystone National Policy Dialogue on Establishment of Studies to Optimize Medical Management of HIV Infection," which called for an ongoing collaboration among stakeholders to address emerging issues in HIV/...

Biotectix, LLC

Biotectix is developing a new class of conductive polymer materials and coatings for implantable devices and sensors that improve the safety, longevity, reliability, biological integration, and function of implantable biomedical devices. A number of benefits are driven by this platform technology without changing device size, shape, or implant procedure, i...

Molecular Response

Molecular Response is a leader in advancing targeted therapeutics through intelligently designed, clinically validated companion diagnostics. Our goal is to reduce risk and increase the efficacy of therapeutic drug development for our partners by translating clinically relevant molecular response marker data into high-value knowledge while fully integrated...

Sean N. Parker Center for Allergy Research at Stanford University

Thanks to the support of philanthropic leaders, Stanford University School of Medicine has established an interdisciplinary and interdependent allergy research center that makes transformative changes for patients and their families through innovative science, collaborative research and compassionate care. The Center will bring together top-ranked scientis...

Theraclone Sciences, Inc.

Theraclone Sciences is a Seattle‐based biotechnology company focused on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer. The company’s technology harnesses the power of the human immune system to identify rare, naturally evolved antibodies from the blood cells of immunologically relevant human su...

EMD LEXIGEN

Founded in 1992 as a joint venture with Fuji Photo Film Ltd., EMD Lexigen Research Center Corp. (EMD Lexigen for short) was formed to screen Fuji’s chemical library for drug activities, with an initial focus on immune disorders and cancer.Our activities have evolved significantly since then. Having gained independence from Fuji Photo Film in 1997, EMD Lexigen has honed its activities to focus on...


More From BioPortfolio on "Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks